{
  "docId": "019de072-0f48-75dc-8e26-6c36719c246a",
  "docSlug": "59aa3600901f9a5fdbc1ca4ce261b5cc",
  "documentTitle": "Vigil Neuroscience | IPO Presentation Deck | 54 slides",
  "authorId": "vigil-neuroscience",
  "authorName": "Vigil Neuroscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 28,
  "pageCount": 54,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 9,
  "notes": "PoM = Proof of Mechanism; ALSP = Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0f48-75dc-8e26-6c36719c246a/28",
  "deckHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a",
  "deckJsonHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a.json",
  "deckAnchorHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.081
      },
      "kind": "callout",
      "text": "TREM2 agonism compensates for CSF1/CSF1R loss of signaling in microglia – additional in vitro PoM for ALSP",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "824377d3-e0ec-41bb-8cf6-44a513e70332",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.25,
        "y": 0.18
      },
      "kind": "chart",
      "text": "VGL101 Restored Human Microglial Survival Following CSF1 Withdrawal",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f51a1ce3-72c2-4efe-ab4b-2e20d1cdfc40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Y-axis (% Rescue Media as Control): survival of microglia culture based on levels of adenosine triphosphate generation... n.s. – not statistically significant vs Withdrawal Media; * – adjusted p-value < 0.05 vs Withdrawal Media; *** – adjusted p-value < 0.001 vs Withdrawal Media",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58e6fce9-441a-4dce-92f3-ac68f38faa95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Additional In Vitro PoM: VGL101 Restored Microglia Survival Following CSF1 Withdrawal",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a50a0fa-4411-4fbd-8cf4-5833bd25c197",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Evidence Matrix",
      "slug": "evidence-matrix",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "db06594e-2441-4fe1-8645-1f9b1285a7c3",
      "evidence": "The slide provides additional in vitro proof of mechanism for ALSP, using data to support the effectiveness of TREM2 agonism.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 23,
      "beatId": "e3eb75f6-e675-4e37-8bf9-f4d5dbfb68fe",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents a clear problem statement and an explanation of the unmet medical need in neurodegenerative diseases.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e2005ee6-5f9f-4463-b0ef-3ff73d5299ad",
      "evidence": "The document presents the unmet medical need in ALSP and the potential benefits of treating it.",
      "position": 0,
      "objective": "What is the cost of not treating ALSP?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}